Dynavax Teams Up with Medigen on COVID-19 Vaccine

Dynavax has partnered with Taiwan-based Medigen Vaccine Biologics to develop an adjuvanted COVID-19 vaccine candidate.

The partnership will evaluate Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein with Dynavax’s adjuvant CpG1018, which is used in its hepatitis B vaccine.

Preclinical studies have demonstrated that the vaccine candidate with the adjuvant generates strong immune responses in animals.